Эпигенетические Факторы Развития Неактивных Аденом Гипофиза (Обзор Литературы)
Keywords:
эпигенетические факторы, микроРНК, неактивная аденома гипофиза, маркёры патогенеза
Abstract
В настоящем обзоре освещаются вопросы эпигенетических факторов развития неактивных аденом гипофиза, текущие тенденции и отдельные методологии изучения молекулярных структур, фармакологическая активность в эпигеноме, описана краткая характеристика молекулярного фона эпигенетических регуляторных механизмов, а также представлены данные, касающиеся изучению микроРНК в качестве предикторов онкогенеза, терапевтических мишеней и новых биомаркеров развития данной патологии.
References
1. Гареев И. Ф., Бейлерли О. А. Изучение роли микроРНК при аденоме гипофиза. Успехи молекулярной онкологии // № 2, 2018 г., стр. 8-15
2. Гребенникова Т.А., Белая Ж.Е., Рожинская Л.Я., и др. Эпигенетические аспекты остеопороза // Вестник Российской академии медицинских наук. ― 2015. ― Т.70. ― №5 ― С. 541–548.
3. Луценко А.С., Белая Ж.Е., Пржиялковская Е.Г., Мельниченко Г.А. МикроРНК и их значение в патогенезе СТГ-продуцирующих аденом гипофиза. // Актуальные вопросы эндокринологии. 2017; 72 (4):290–298. doi: 10.15690/vramn856
4. Мустафин Р. Н., Хуснутдинова Э. К. Эпигенетика канцерогенеза. Креативная хирургия и онкология 2017;7(3): 60–7. DOI: 10.24060/2076-3093-2017-7-3-60-67.
5. Швангирадзе Т.А, Бондаренко И.З., Трошина Е.А., и др. Профиль микроРНК, ассоциированных с ИБС, у пациентов с сахарным диабетом 2 типа // Ожирение и метаболизм. — 2016. — Т.13. — №4 — С. 34–38.
6. Alegría-Torres, J.A.;Baccarelli,A.; Bollati,V. Epigenetics and lifestyle. Epigenomics 2011, 3,267–277.
7. Aloy, P.; Russell, R.B. Structural systems biology: Modelling protein interactions. Nat. Rev. Mol. Cell Biol. 2006, 7, 188–197. Int. J. Mol. Sci. 2020, 21
8. Asa SL, Ezzat S. The pathogenesis of pituitary tumours. Nat Rev Cancer. 2002; 2(11):836–849. doi: 10.1038/nrc926.
9. Balázs Zoltán Zsidó and Csaba Hetényi. Molecular Structure, Binding Affinity, and Biological Activity in the Epigenome. // International Journal of Molecular Sciences. 2020, 21, 4134; doi:10.3390/ijms21114134
10. Bah, A.; Vernon, R.M.; Siddiqui, Z.; Krzeminski, M.; Muhandiram, R.; Zhao, C.; Sonenberg, N.; Kay, L.E.; Forman-Kay, J.D. Folding of an intrinsically disordered protein by phosphorylation as a regulatory switch. Nature 2015, 519, 106–109.
11. Berman, H.M.; Battistuz, T.; Bhat, T.N.; Bluhm, W.F.; Bourne, P.E.; Burkhardt, K.; Feng, Z.; Gilliland, G.L.; Iype, L.; Jain, S.; et al. The protein data bank. Acta Cryst. Sect. D Biol. Cryst. 2002, 58, 899–907.
12. Berdasco, M.; Esteller, M. Clinical epigenetics: Seizing opportunities for translation. Nat. Rev. Genet. 2019, 20, 109–127.
13. Bird, A. Perceptions of epigenetics. Nature 2007, 447, 396–398.
14. Bottoni A, Piccin D, Tagliati F, et al. miR-15a and miR-16-1 down-regulation in pituitary adenomas. J Cell Physiol. 2005;204(1):280–285. doi: 10.1002/jcp.20282.
15. Bottoni A, Zatelli MC, Ferracin M, et al. Identification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary adenomas. J Cell Physiol. 2007;210(2):370–377. doi: 10.1002/jcp.20832.
16. Bleicken, S.; Hantusch, A.; Das, K.K.; Frickey, T.; Garcia-Saez, A.J. Quantitative interactome of a membrane Bcl-2 network identifies a hierarchy of complexes for apoptosis regulation. Nat. Commun. 2017, 8, 73.
17. Bragg, W.H.; Bragg, W.L. The structure of the diamond. Nature 1913, 91, 557.
18. Brink, C.; Hodgkin, D.; Lindsey, Y.; Pickworth, J.; Robertson, J.H.; White, J.G. Structure of vitamin B12: X-ray crystallographic evidence on the structure of vitamin B12. Nature 1954, 174, 1169–1171.
19. Butz H, Liko I, Czirjak S, et al. MicroRNA profile indicates downregulation of the TGFbeta pathway in sporadic non-functioning pituitary adenomas. Pituitary. 2011; 14(2):112–124. doi: 10.1007/s11102-010-0268-x.
20. Chi YD, Zhou DM. MicroRNAs in colorectal carcinoma - from pathogenesis to therapy. J Exp Clin Cancer Res. 2016;35:43. doi: ARTN 4310.1186/s13046-016-0320-4.
21. D’Angelo D, Esposito F, Fusco A. Epigenetic mechanisms leading to overexpression of HMGA proteins in human pituitary adenomas. Front Med (Lausanne). 2015; 2:39. doi: 10.3389/fmed.2015.00039.
22. Feinberg, A.P.; Tycko, B. The history of cancer epigenetics. Nat. Rev. Cancer 2004, 4, 143–153.
23. Feinberg, A.P.; Koldobskiy, M.A.; Göndör, A. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat. Rev. Genet. 2016, 17, 284–299.
24. Gamblin, S.J.; Wilson, J.R. A key to unlock chromatin. Nature 2019, 573, 354–355.
25. Gentilin E, Di Pasquale C, Gagliano T, et al. Protein Kinase C Delta restrains growth in ACTH-secreting pituitary adenoma cells. Mol Cell Endocrinol. 2016;419:252-258. doi: 10.1016/j.mce.2015.10.025.
26. Henry J. C., Azevedo-Pouly A. C., Schmittgen T. D. MicroRNA replacement therapy for cancer. Pharm Res 2011; 28(12): 3030–42. DOI: 10.1007/s11095-011-054. PMID: 21879389.
27. Holliday, R. Epigenetics: A historical overview. Epigenetics 2006, 1, 76–80.
28. Izzo, L.T.; Wellen, K.E. Histone lactylation links metabolism and gene regulation. Nature 2019, 574, 492–493.
29. Jemth, P.; Karlsson, E.; Vögeli, B.; Guzovsky, B.; Andersson, E.; Hultqvist, G.; Dogan, J.; Güntert, P.; Riek, R.;Chi, C.N. Structure and dynamics conspire in the evolution of affinity between intrinsically disordered proteins. Sci. Adv. 2018, 4, 4130–4144.
30. Jordan S. D., Kruger M., Willmes D. M. et al. Obesity-induced overexpression of miRNA-143 inhibits insulin-stimulated AKT activation and impairs glucose metabolism. Nat Cell Biol 2011; 13(4):434–46. DOI: 10.1038/ncb2211. PMID: 21441927.
31. Kelly B. N., Haverstick D. M., Lee J. K. et al. Circulating microRNA as a biomarker of human growth hormone administration to patients. Drug Test Anal 2014; 6 (3):234–8. DOI: 10.1002/dta.1469. PMID: 23495241.
32. Khoshnevisan A, Parvin M, Ghorbanmehr N, et al. A significant upregulation of miR5-886-p in high grade and invasive bladder tumors. Urol J. 2015;12(3):2160–2164.
33. Kroh EM, Parkin RK, Mitchell PS, Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using 297 quantitative reverse transcription-PCR (qRT-PCR). Methods. 2010;50(4):298–301. doi: 10.1016/j.ymeth.2010.01.032.
34. Kuwabara Y, Ono K, Horie T, et al. Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. Circ Cardiovasc Genet. 2011;4(4):446–454. doi: 10.1161/circgenetics.110.958975.
35. Lappalainen, T.; Greally, J.M. Associating cellular epigenetic models with human phenotypes. Nat. Rev. Genet. 2017, 18, 441–451.
36. Li XH, Wang EL, Zhou HM, et al. MicroRNAs in human pituitary adenomas. Int J Endocrinol. 2014;2014:435171. doi: 10.1155/2014/435171.
37. Mao ZG, He DS, Zhou J, et al. Differential expression of microRNAs in GH-secreting pituitary adenomas. Diagn Pathol. 2010;5:79. doi: 10.1186/1746-1596-5-79.
38. Mews, P.; Egervari, G.; Nativio, R.; Sidoli, S.; Donahue, G.; Lombroso, S.I.; Alexander, D.C.; Riesche, S.L.; Heller, E.A.; Nestler, E.J.; et al. Alcohol metabolism contributes to brain histone acetylation. Nature 2019, 574, 717–721. 39. Monk, D.; Mackay, D.J.G.; Eggermann, T.; Maher, E.R.; Riccio, A. Genomic imprinting disorders: Lessons on how genome, epigenome and environment interact. Nat. Rev. Genet. 2019, 20, 235–248.
39. Mosca, R.; Céol, A.; Aloy, P. Interactome3D: Adding structural details to protein networks. Nat. Methods 2013, 10, 47–53.
40. Pinzi, L.; Rastelli, G. Molecular docking: Shifting paradigms in drug discovery. Int. J. Mol. Sci. 2019, 20, 4331.
41. Peinado H, Lavotshkin S, Lyden D. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin Cancer Biol. 2011; 21(2):139–146. doi: 10.1016/j.semcancer.2011.01.002.
42. Quereda V, Malumbres M. Cell cycle control of pituitary development and disease. J Mol Endocrinol. 2009; 42(2):75–86. doi: 10.1677/Jme-08-0146.
43. Riggs, A.D.; Martienssen, R.A.; Russo, V.E.A. Introduction. In Epigenetic Mechanisms of Gene Regulation, 1st ed.; Russo, V.E.A., Ed.; Cold Spring Harbor Laboratory Press: Huntington, NY, USA, 1996; pp. 1–14.
44. Rossi S, Calin GA. Bioinformatics, non-coding RNAs and its possible application in personalized medicine. Adv Exp Med Biol. 2013; 774:21–37. doi: 10.1007/978-94-007-5590-1_2.
45. Shi X., Tao B., He H. et al. MicroRNAs-based network: a novel therapeutic agent in pituitary adenoma. Med Hypotheses 2012; 78(3):380–4. DOI: 10.1016/ j.mehy.2011.12.001. PMID: 22222153.
46. Stricker, S.H.; Köferle, A.; Beck, S. From profiles to function in epigenomics. Nat. Rev. Genet. 2016, 18, 51–66.
47. Waddington, C.H. The Strategy of the Genes, 1st ed.; Routledge: New York, NY, USA, 1957; pp. 1–32.
48. Wang Q., Li P., Li A. et al. Plasma specific miRNAs as predictive biomarkers for diagnosis and prognosis of glioma. J Exp Clin Cancer Res 2012;31:97. DOI: 10.1186/1756-9966-31-97. PMID: 23174013.
49. Wang J, Chen JY, Sen S. MicroRNA as biomarkers and diagnostics. J Cell Physiol. 2016; 231(1):25–30. doi: 10.1002/jcp.25056. 16. Weber JA, Baxter DH, Zhang SL, et al. The microRNA spectrum in 12 body fluids. Clin Chem. 2010; 56(11):1733–1741. doi: 10.1373/clinchem.2010.147405.
50. Wright, P.E.; Dyson, H.J. intrinsically disordered proteins in cellular signaling and regulation. Nat. Rev. Mol. Cell Biol. 2015, 16, 18–29.
51. Zen K., Zhang C. Y. Circulating microR-NAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev 2012; 32(2):326–48. DOI: 10.1002/ med.20215. PMID: 22383180.
2. Гребенникова Т.А., Белая Ж.Е., Рожинская Л.Я., и др. Эпигенетические аспекты остеопороза // Вестник Российской академии медицинских наук. ― 2015. ― Т.70. ― №5 ― С. 541–548.
3. Луценко А.С., Белая Ж.Е., Пржиялковская Е.Г., Мельниченко Г.А. МикроРНК и их значение в патогенезе СТГ-продуцирующих аденом гипофиза. // Актуальные вопросы эндокринологии. 2017; 72 (4):290–298. doi: 10.15690/vramn856
4. Мустафин Р. Н., Хуснутдинова Э. К. Эпигенетика канцерогенеза. Креативная хирургия и онкология 2017;7(3): 60–7. DOI: 10.24060/2076-3093-2017-7-3-60-67.
5. Швангирадзе Т.А, Бондаренко И.З., Трошина Е.А., и др. Профиль микроРНК, ассоциированных с ИБС, у пациентов с сахарным диабетом 2 типа // Ожирение и метаболизм. — 2016. — Т.13. — №4 — С. 34–38.
6. Alegría-Torres, J.A.;Baccarelli,A.; Bollati,V. Epigenetics and lifestyle. Epigenomics 2011, 3,267–277.
7. Aloy, P.; Russell, R.B. Structural systems biology: Modelling protein interactions. Nat. Rev. Mol. Cell Biol. 2006, 7, 188–197. Int. J. Mol. Sci. 2020, 21
8. Asa SL, Ezzat S. The pathogenesis of pituitary tumours. Nat Rev Cancer. 2002; 2(11):836–849. doi: 10.1038/nrc926.
9. Balázs Zoltán Zsidó and Csaba Hetényi. Molecular Structure, Binding Affinity, and Biological Activity in the Epigenome. // International Journal of Molecular Sciences. 2020, 21, 4134; doi:10.3390/ijms21114134
10. Bah, A.; Vernon, R.M.; Siddiqui, Z.; Krzeminski, M.; Muhandiram, R.; Zhao, C.; Sonenberg, N.; Kay, L.E.; Forman-Kay, J.D. Folding of an intrinsically disordered protein by phosphorylation as a regulatory switch. Nature 2015, 519, 106–109.
11. Berman, H.M.; Battistuz, T.; Bhat, T.N.; Bluhm, W.F.; Bourne, P.E.; Burkhardt, K.; Feng, Z.; Gilliland, G.L.; Iype, L.; Jain, S.; et al. The protein data bank. Acta Cryst. Sect. D Biol. Cryst. 2002, 58, 899–907.
12. Berdasco, M.; Esteller, M. Clinical epigenetics: Seizing opportunities for translation. Nat. Rev. Genet. 2019, 20, 109–127.
13. Bird, A. Perceptions of epigenetics. Nature 2007, 447, 396–398.
14. Bottoni A, Piccin D, Tagliati F, et al. miR-15a and miR-16-1 down-regulation in pituitary adenomas. J Cell Physiol. 2005;204(1):280–285. doi: 10.1002/jcp.20282.
15. Bottoni A, Zatelli MC, Ferracin M, et al. Identification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary adenomas. J Cell Physiol. 2007;210(2):370–377. doi: 10.1002/jcp.20832.
16. Bleicken, S.; Hantusch, A.; Das, K.K.; Frickey, T.; Garcia-Saez, A.J. Quantitative interactome of a membrane Bcl-2 network identifies a hierarchy of complexes for apoptosis regulation. Nat. Commun. 2017, 8, 73.
17. Bragg, W.H.; Bragg, W.L. The structure of the diamond. Nature 1913, 91, 557.
18. Brink, C.; Hodgkin, D.; Lindsey, Y.; Pickworth, J.; Robertson, J.H.; White, J.G. Structure of vitamin B12: X-ray crystallographic evidence on the structure of vitamin B12. Nature 1954, 174, 1169–1171.
19. Butz H, Liko I, Czirjak S, et al. MicroRNA profile indicates downregulation of the TGFbeta pathway in sporadic non-functioning pituitary adenomas. Pituitary. 2011; 14(2):112–124. doi: 10.1007/s11102-010-0268-x.
20. Chi YD, Zhou DM. MicroRNAs in colorectal carcinoma - from pathogenesis to therapy. J Exp Clin Cancer Res. 2016;35:43. doi: ARTN 4310.1186/s13046-016-0320-4.
21. D’Angelo D, Esposito F, Fusco A. Epigenetic mechanisms leading to overexpression of HMGA proteins in human pituitary adenomas. Front Med (Lausanne). 2015; 2:39. doi: 10.3389/fmed.2015.00039.
22. Feinberg, A.P.; Tycko, B. The history of cancer epigenetics. Nat. Rev. Cancer 2004, 4, 143–153.
23. Feinberg, A.P.; Koldobskiy, M.A.; Göndör, A. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat. Rev. Genet. 2016, 17, 284–299.
24. Gamblin, S.J.; Wilson, J.R. A key to unlock chromatin. Nature 2019, 573, 354–355.
25. Gentilin E, Di Pasquale C, Gagliano T, et al. Protein Kinase C Delta restrains growth in ACTH-secreting pituitary adenoma cells. Mol Cell Endocrinol. 2016;419:252-258. doi: 10.1016/j.mce.2015.10.025.
26. Henry J. C., Azevedo-Pouly A. C., Schmittgen T. D. MicroRNA replacement therapy for cancer. Pharm Res 2011; 28(12): 3030–42. DOI: 10.1007/s11095-011-054. PMID: 21879389.
27. Holliday, R. Epigenetics: A historical overview. Epigenetics 2006, 1, 76–80.
28. Izzo, L.T.; Wellen, K.E. Histone lactylation links metabolism and gene regulation. Nature 2019, 574, 492–493.
29. Jemth, P.; Karlsson, E.; Vögeli, B.; Guzovsky, B.; Andersson, E.; Hultqvist, G.; Dogan, J.; Güntert, P.; Riek, R.;Chi, C.N. Structure and dynamics conspire in the evolution of affinity between intrinsically disordered proteins. Sci. Adv. 2018, 4, 4130–4144.
30. Jordan S. D., Kruger M., Willmes D. M. et al. Obesity-induced overexpression of miRNA-143 inhibits insulin-stimulated AKT activation and impairs glucose metabolism. Nat Cell Biol 2011; 13(4):434–46. DOI: 10.1038/ncb2211. PMID: 21441927.
31. Kelly B. N., Haverstick D. M., Lee J. K. et al. Circulating microRNA as a biomarker of human growth hormone administration to patients. Drug Test Anal 2014; 6 (3):234–8. DOI: 10.1002/dta.1469. PMID: 23495241.
32. Khoshnevisan A, Parvin M, Ghorbanmehr N, et al. A significant upregulation of miR5-886-p in high grade and invasive bladder tumors. Urol J. 2015;12(3):2160–2164.
33. Kroh EM, Parkin RK, Mitchell PS, Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using 297 quantitative reverse transcription-PCR (qRT-PCR). Methods. 2010;50(4):298–301. doi: 10.1016/j.ymeth.2010.01.032.
34. Kuwabara Y, Ono K, Horie T, et al. Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. Circ Cardiovasc Genet. 2011;4(4):446–454. doi: 10.1161/circgenetics.110.958975.
35. Lappalainen, T.; Greally, J.M. Associating cellular epigenetic models with human phenotypes. Nat. Rev. Genet. 2017, 18, 441–451.
36. Li XH, Wang EL, Zhou HM, et al. MicroRNAs in human pituitary adenomas. Int J Endocrinol. 2014;2014:435171. doi: 10.1155/2014/435171.
37. Mao ZG, He DS, Zhou J, et al. Differential expression of microRNAs in GH-secreting pituitary adenomas. Diagn Pathol. 2010;5:79. doi: 10.1186/1746-1596-5-79.
38. Mews, P.; Egervari, G.; Nativio, R.; Sidoli, S.; Donahue, G.; Lombroso, S.I.; Alexander, D.C.; Riesche, S.L.; Heller, E.A.; Nestler, E.J.; et al. Alcohol metabolism contributes to brain histone acetylation. Nature 2019, 574, 717–721. 39. Monk, D.; Mackay, D.J.G.; Eggermann, T.; Maher, E.R.; Riccio, A. Genomic imprinting disorders: Lessons on how genome, epigenome and environment interact. Nat. Rev. Genet. 2019, 20, 235–248.
39. Mosca, R.; Céol, A.; Aloy, P. Interactome3D: Adding structural details to protein networks. Nat. Methods 2013, 10, 47–53.
40. Pinzi, L.; Rastelli, G. Molecular docking: Shifting paradigms in drug discovery. Int. J. Mol. Sci. 2019, 20, 4331.
41. Peinado H, Lavotshkin S, Lyden D. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin Cancer Biol. 2011; 21(2):139–146. doi: 10.1016/j.semcancer.2011.01.002.
42. Quereda V, Malumbres M. Cell cycle control of pituitary development and disease. J Mol Endocrinol. 2009; 42(2):75–86. doi: 10.1677/Jme-08-0146.
43. Riggs, A.D.; Martienssen, R.A.; Russo, V.E.A. Introduction. In Epigenetic Mechanisms of Gene Regulation, 1st ed.; Russo, V.E.A., Ed.; Cold Spring Harbor Laboratory Press: Huntington, NY, USA, 1996; pp. 1–14.
44. Rossi S, Calin GA. Bioinformatics, non-coding RNAs and its possible application in personalized medicine. Adv Exp Med Biol. 2013; 774:21–37. doi: 10.1007/978-94-007-5590-1_2.
45. Shi X., Tao B., He H. et al. MicroRNAs-based network: a novel therapeutic agent in pituitary adenoma. Med Hypotheses 2012; 78(3):380–4. DOI: 10.1016/ j.mehy.2011.12.001. PMID: 22222153.
46. Stricker, S.H.; Köferle, A.; Beck, S. From profiles to function in epigenomics. Nat. Rev. Genet. 2016, 18, 51–66.
47. Waddington, C.H. The Strategy of the Genes, 1st ed.; Routledge: New York, NY, USA, 1957; pp. 1–32.
48. Wang Q., Li P., Li A. et al. Plasma specific miRNAs as predictive biomarkers for diagnosis and prognosis of glioma. J Exp Clin Cancer Res 2012;31:97. DOI: 10.1186/1756-9966-31-97. PMID: 23174013.
49. Wang J, Chen JY, Sen S. MicroRNA as biomarkers and diagnostics. J Cell Physiol. 2016; 231(1):25–30. doi: 10.1002/jcp.25056. 16. Weber JA, Baxter DH, Zhang SL, et al. The microRNA spectrum in 12 body fluids. Clin Chem. 2010; 56(11):1733–1741. doi: 10.1373/clinchem.2010.147405.
50. Wright, P.E.; Dyson, H.J. intrinsically disordered proteins in cellular signaling and regulation. Nat. Rev. Mol. Cell Biol. 2015, 16, 18–29.
51. Zen K., Zhang C. Y. Circulating microR-NAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev 2012; 32(2):326–48. DOI: 10.1002/ med.20215. PMID: 22383180.
Published
2022-05-04
How to Cite
Шарифовна, Х. Д., & Юсуповна, Х. З. (2022). Эпигенетические Факторы Развития Неактивных Аденом Гипофиза (Обзор Литературы). Central Asian Journal of Medical and Natural Science, 3(2), 535-542. Retrieved from https://cajmns.centralasianstudies.org/index.php/CAJMNS/article/view/709
Section
Articles
